Kinetics of antibody responses after primary immunization with meningococcal serogroup C conjugate vaccine or secondary immunization with either conjugate or polysaccharide vaccine in adults

Vaccine

Volumn 27, Issue 50, 2009, Pages 6974-6982

  de Voer, Richarda M ^a,b   van der Klis, Fiona R M ^a   Engels, Carla W A M ^b   Schepp, Rutger M ^a   van de Kassteele, Jan ^a   Sanders, Elisabeth A M ^b   Rijkers, Ger T ^b,c   Berbers, Guy A M ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

Antibodies; Conjugate; Kinetics; Meningococcal; Serogroup C

Indexed keywords

IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN M ANTIBODY; MENINGOCOCCUS SEROGROUP C CONJUGATE VACCINE; MENINGOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; TETANUS TOXIN; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNIZATION; NORMAL HUMAN; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; ANTIBODY AFFINITY; ANTIBODY FORMATION; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; MIDDLE AGED; NETHERLANDS; YOUNG ADULT;

EID: 70449095879     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.09.082     Document Type: Article

References (51)

1. Gezondheidsraad/Health Council of the Netherlands. Universal vaccination against meningococcal serogroup C and pneumococcal disease (2002), The Hague No. 2001/27E
2. de Greeff S.C., de Melker H.E., Spanjaard L., Schouls L.M., and van Der Ende A. Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands. Pediatr Infect Dis J 25 1 (2006) 79-80
3. Richmond P., Borrow R., Goldblatt D., Findlow J., Martin S., Morris R., et al. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J Infect Dis 183 1 (2001) 160-163
4. Richmond P., Goldblatt D., Fusco P.C., Fusco J.D., Heron I., Clark S., et al. Safety and immunogenicity of a new Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in healthy adults. Vaccine 18 7-8 (1999) 641-646
5. Richmond P., Borrow R., Miller E., Clark S., Sadler F., Fox A., et al. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J Infect Dis 179 6 (1999) 1569-1572
6. Kelly D.F., Snape M.D., Clutterbuck E.A., Green S., Snowden C., Diggle L., et al. CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cells. Blood 108 8 (2006) 2642-2647
7. Borrow R., Andrews N., Goldblatt D., and Miller E. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immun 69 3 (2001) 1568-1573
8. Borrow R., Goldblatt D., Andrews N., Southern J., Ashton L., Deane S., et al. Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United kingdom. J Infect Dis 186 9 (2002) 1353-1357
9. Snape M.D., Kelly D.F., Green B., Moxon E.R., Borrow R., and Pollard A.J. Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine. Pediatr Infect Dis J 24 2 (2005) 128-131
10. Snape M.D., Kelly D.F., Lewis S., Banner C., Kibwana L., Moore C.E., et al. Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study. BMJ 336 7659 (2008) 1487-1491
11. Tsai T.F., Borrow R., Gnehm H.E., Vaudaux B., Heininger U., Desgrandchamps D., et al. Early appearance of bactericidal antibodies after polysaccharide challenge of toddlers primed with a group C meningococcal conjugate vaccine: what is its role in the maintenance of protection?. Clin Vaccine Immunol 13 8 (2006) 854-861
12. Blanchard-Rohner G., Snape M.D., Kelly D.F., John T., Morant A., Yu L.M., et al. The magnitude of the antibody and memory B cell responses during priming with a protein-polysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster response. J Immunol 180 4 (2008) 2165-2173
13. de Voer R.M., van der Klis F.R.M., Engels C.W.A.M., Rijkers G.T., Sanders E.A.M., and Berbers G.A.M. Development of a fluorescent-bead-based multiplex immunoassay to determine immunoglobulin G subclass responses to Neisseria meningitidis serogroup A and C polysaccharides. Clin Vaccine Immunol 15 8 (2008) 1188-1193
14. Lal G., Balmer P., Joseph H., Dawson M., and Borrow R. Development and evaluation of a tetraplex flow cytometric assay for quantitation of serum antibodies to Neisseria meningitidis serogroups A, C, Y, and W-135. Clin Diagn Lab Immunol 11 2 (2004) 272-279
15. van Gageldonk P.G., van Schaijk F.G., van der Klis F.R.M., and Berbers G.A.M. Development and validation of a multiplex immunoassay for the simultaneous determination of serum antibodies to Bordetella pertussis, diphtheria and tetanus. J Immunol Methods 335 1-2 (2008) 79-89
16. Maslanka S.E., Gheesling L.L., Libutti D.E., Donaldson K.B., Harakeh H.S., Dykes J.K., et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. Clin Diagn Lab Immunol 4 2 (1997) 156-167
17. Anttila M., Eskola J., Ahman H., and Kayhty H. Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines. J Infect Dis 177 6 (1998) 1614-1621
18. Pinheiro J., and Bates D. Mixed-effects models in S and S-PLUS (2002), Springer, New York
19. Pennridge Pediatric Associates, Madore D.V., Johnson-Kraines C.L., Rothstein E.P., and Smith D.H. Kinetics of antibody response to Haemophilus influenzae type b vaccines. Curr Med Res Opin 15 2 (1999) 105-112
20. Borrow R., Southern J., Andrews N., Peake N., Rahim R., Acuna M., et al. Comparison of antibody kinetics following meningococcal serogroup C conjugate vaccine between healthy adults previously vaccinated with meningococcal A/C polysaccharide vaccine and vaccine-naive controls. Vaccine 19 23-24 (2001) 3043-3050
21. Nieminen T., Kayhty H., and Kantele A. Circulating antibody secreting cells and humoral antibody response after parenteral immunization with a meningococcal polysaccharide vaccine. Scand J Infect Dis 28 1 (1996) 53-58
22. Trotter C.L., Borrow R., Findlow J., Holland A., Frankland S., Andrews N.J., et al. Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era. Clin Vaccine Immunol 15 11 (2008) 1694-1698
23. Crotty S., and Ahmed R. Immunological memory in humans. Semin Immunol 16 3 (2004) 197-203
24. Pihlgren M., Friedli M., Tougne C., Rochat A.F., Lambert P.H., and Siegrist C.A. Reduced ability of neonatal and early-life bone marrow stromal cells to support plasmablast survival. J Immunol 176 1 (2006) 165-172
25. Pihlgren M., Schallert N., Tougne C., Bozzotti P., Kovarik J., Fulurija A., et al. Delayed and deficient establishment of the long-term bone marrow plasma cell pool during early life. Eur J Immunol 31 3 (2001) 939-946
26. Bernasconi N.L., Traggiai E., and Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298 5601 (2002) 2199-2202
27. DiLillo D.J., Hamaguchi Y., Ueda Y., Yang K., Uchida J., Haas K.M., et al. Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J Immunol 180 1 (2008) 361-371
28. Snape M.D., Kelly D.F., Salt P., Green S., Snowden C., Diggle L., et al. Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization. Clin Infect Dis 43 11 (2006) 1387-1394
29. Goldblatt D., Vaz A.R., and Miller E. Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. J Infect Dis 177 4 (1998) 1112-1115
30. Wuorimaa T., Dagan R., Vakevainen M., Bailleux F., Haikala R., Yaich M., et al. Avidity and subclasses of IgG after immunization of infants with an 11-valent pneumococcal conjugate vaccine with or without aluminum adjuvant. J Infect Dis 184 9 (2001) 1211-1215
31. Maiden M.C., and Stuart J.M. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 359 9320 (2002) 1829-1831
32. Borrow R., Fox A.J., Cartwright K., Begg N.T., and Jones D.M. Salivary antibodies following parenteral immunization of infants with a meningococcal serogroup A and C conjugated vaccine. Epidemiol Infect 123 2 (1999) 201-208
33. Zhang Q., Choo S., Everard J., Jennings R., and Finn A. Mucosal immune responses to meningococcal group C conjugate and group A and C polysaccharide vaccines in adolescents. Infect Immun 68 5 (2000) 2692-2697
34. Schouls LM, de Greeff SC. RIVM Report: The National Immunisation Programme in the Netherlands. 2008; 210021008/2008. p 34.
35. Burrage M., Robinson A., Borrow R., Andrews N., Southern J., Findlow J., et al. Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection. Infect Immun 70 9 (2002) 4946-4954
36. Schutze M.P., Leclerc C., Jolivet M., Audibert F., and Chedid L. Carrier-induced epitopic suppression, a major issue for future synthetic vaccines. J Immunol 135 4 (1985) 2319-2322
37. Sad S., Gupta H.M., Talwar G.P., and Raghupathy R. Carrier-induced suppression of the antibody response to a 'self' hapten. Immunology 74 2 (1991) 223-227
38. Pollabauer E.M., Petermann R., and Ehrlich H.J. The influence of carrier protein on the immunogenicity of simultaneously administered conjugate vaccines in infants. Vaccine 27 11 (2009) 1674-1679
39. Panpitpat C., Thisyakorn U., Chotpitayasunondh T., Furer E., Que J.U., Hasler Tl, et al. Elevated levels of maternal anti-tetanus toxin antibodies do not suppress the immune response to a Haemophilus influenzae type b polyribosylphosphate-tetanus toxoid conjugate vaccine. Bull World Health Organ 78 3 (2000) 364-371
40. Dagan R., Eskola J., Leclerc C., and Leroy O. Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants. Infect Immun 66 5 (1998) 2093-2098
41. Nanan R., Heinrich D., Frosch M., and Kreth H.W. Acute and long-term effects of booster immunisation on frequencies of antigen-specific memory B-lymphocytes. Vaccine 20 3-4 (2001) 498-504
42. Kruetzmann S., Rosado M.M., Weber H., Germing U., Tournilhac O., Peter H.H., et al. Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen. J Exp Med 197 7 (2003) 939-945
43. Weller S., Braun M.C., Tan B.K., Rosenwald A., Cordier C., Conley M.E., et al. Human blood IgM "memory" B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire. Blood 104 12 (2004) 3647-3654
44. Weller S., Reynaud C.A., and Weill J.C. Vaccination against encapsulated bacteria in humans: paradoxes. Trends Immunol 26 2 (2005) 85-89
45. Lottenbach K.R., Mink C.M., Barenkamp S.J., Anderson E.L., Homan S.M., and Powers D.C. Age-associated differences in immunoglobulin G1 (IgG1) and IgG2 subclass antibodies to pneumococcal polysaccharides following vaccination. Infect Immun 67 9 (1999) 4935-4938
46. Soininen A., Seppala I., Nieminen T., Eskola J., and Kayhty H. IgG subclass distribution of antibodies after vaccination of adults with pneumococcal conjugate vaccines. Vaccine 17 15-16 (1999) 1889-1897
47. Findlow H., Southern J., Mabey L., Balmer P., Heyderman R.S., Auckland C., et al. Immunoglobulin G subclass response to a meningococcal quadrivalent polysaccharide-diphtheria toxoid conjugate vaccine. Clin Vaccine Immunol 13 4 (2006) 507-510
48. Makela O., Mattila P., Rautonen N., Seppala I., Eskola J., and Kayhty H. Isotype concentrations of human antibodies to Haemophilus influenzae type b polysaccharide (Hib) in young adults immunized with the polysaccharide as such or conjugated to a protein (diphtheria toxoid). J Immunol 139 6 (1987) 1999-2004
49. Rautonen N., Pelkonen J., Sipinen S., Kayhty H., and Makela O. Isotype concentrations of human antibodies to group A meningococcal polysaccharide. J Immunol 137 8 (1986) 2670-2675
50. Barrett D.J., and Ayoub E.M. IgG2 subclass restriction of antibody to pneumococcal polysaccharides. Clin Exp Immunol 63 1 (1986) 127-134
51. Bredius R.G., Driedijk P.C., Schouten M.F., Weening R.S., and Out T.A. Complement activation by polyclonal immunoglobulin G1 and G2 antibodies against Staphylococcus aureus, Haemophilus influenzae type b, and tetanus toxoid. Infect Immun 60 11 (1992) 4838-4847